Search Results - "Carabantes, F"

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer by Blancas, I., Olier, C., Conde, V., Bayo, J. L., Herrero, C., Zarcos-Pedrinaci, I., Carabantes, F., Baena-Cañada, J. M., Cruz, J., Ruiz-Borrego, M.

“…Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of…”
Get full text

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study by Ruíz-Borrego, Manuel, Guerrero-Zotano, Angel, Bermejo, Begoña, Ramos, Manuel, Cruz, Josefina, Baena-Cañada, Jose Manuel, Cirauqui, Beatriz, Rodríguez-Lescure, Álvaro, Alba, Emilio, Martínez-Jáñez, Noelia, Muñoz, Montserrat, Antolín, Silvia, Álvarez, Isabel, Del Barco, Sonia, Sevillano, Elena, Chacón, José Ignacio, Antón, Antonio, Escudero, María José, Ruiz, Victoria, Carrasco, Eva, Martín, Miguel

“…Purpose GEICAM/2006–10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is…”
Get full text

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression by Ribelles, N, López-Siles, J, Sánchez, A, González, E, Sánchez, M J, Carabantes, F, Sánchez-Rovira, P, Márquez, A, Dueñas, R, Sevilla, I, Alba, E

“…Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase…”
Get more information

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain by Ciruelos, E., Vidal, M., Martínez de Dueñas, E., Martínez-Jáñez, N., Fernández, Y., García-Sáenz, J. A., Murillo, L., Carabantes, F., Beliera, A., Fonseca, R., Gavilá, J.

“…Background Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced…”
Get full text

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…Introduction This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic…”
Get full text

Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…A sentence under ‘Results’ heading in the Abstract section was published incorrectly. The correct sentence should read as follows:…”
Get full text

Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study by Jolis, L., Carabantes, F., Pernas, S., Cantos, B., López, A., Torres, P., Funes, C., Caballero, D., Benedit, P., Salar, A.

“…We aimed to describe the incidence of neutropenia in breast cancer and lymphoma patients and granulocyte colony‐stimulating factors (G‐CSF) use in clinical…”
Get full text

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced metastatic breast cancer by BATISTA, N, PEREZ-MANGA, G, CASINELLO, J, REGUEIRO, P, MURIAS, A, CONSTENLA, M, RUIZ, A, CARABANTES, F, CASTELLANOS, J, GONZALEZ BARON, M, VILLMAN, K, SÖDERBERG, M, AHLGREN, J

“…The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic…”
Get full text

3074 Darbepoetin alfa for the treatment of chemotherapy-induced anemia in patients with solid tumors by Bustos, A, Carabantes, F, Álvarez, R, Díaz, N, Bueso, P, Lázaro, M, Gasquet, J.A, Alegre, A

Get full text

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer by Benavides, M, García-Alfonso, P, Cobo, M, Muñoz-Martín, A, Gil-Calle, S, Carabantes, F, Villar, E, Graupera, J, Balcells, M, Pérez-Manga, G

“…Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC). Little is known about its efficacy and safety in previously treated…”
Get full text

MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer by Lavado-Valenzuela, R., Benavides, M., Carabantes, F., Alonso, A., Caballero, A.

“…The NKG2D–major histocompatibility complex class I‐related chain A (MICA) system plays a key role in the antitumoral immune response. We studied five alleles…”
Get full text

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

Get full text

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

“…Abstract Aim: After CONFIRM study results, fulvestrant 500 mg (F500) became one of the standard treatments for patients with oestrogen receptor (ER+)…”
Get full text

Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study: Incidence of neutropenia in Spanish cancer patients by Jolis, L., Carabantes, F., Pernas, S., Cantos, B., López, A., Torres, P., Funes, C., Caballero, D., Benedit, P., Salar, A.

Get full text

Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment by Illarramendi, J. J., Blancas, I., Bueso, P., Carabantes, F., Polo Marques, E., Ciruelos Gil, E., Corral, M., Perez, F. J.

“…Abstract only…”
Get full text

Evaluation of clinical use of darbepoetin alfa in patients with chemotherapy-induced anemia by Bustos, A., Cruz, M. A., Aramburo, P., Carabantes, F., Díaz, N., Florián, J., Lázaro, M., Martín de Segovia, J. M., Gasquet, J. A., Alegre, A.

“…Abstract only e20585 Background: Chemotherapy-induced anemia (CIA) is a frequent complication of patients (pts) with cancer and could be treated with…”
Get full text

Different Treatment Benefit for Luminal A and Luminal B Advanced Breast Cancinomas Receiving Aromatase Inhibitors by Ruiz-Borrego, M., Moreno, A., Salvador, J., Carabantes, F., Torregrosa, M., Olmos, T., Martinez, J., de la Haba, J., Valero, M., Martinez, E., Santaballa, A., Hernández, R., Murias, A., Tortorella, A., Guzmán, C., Palacios, J.

“…Background. Aromatase inhibitors (AIs) are indicated for postmenopausal women with hormone receptor (HR) positive metastatic breast cancer. However, at present…”
Get full text

Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases by Aparicio, J., Garcia-Puche, J., Lomas, M., Carabantes, F., Vazquez, S., Crespo, C., Climent, M., Murias, A., Oltra, A., Barrajon, E.

“…Abstract only 4552 Background: The availability of reliable prognostic factors for relapse in stage I seminoma would allow a better patient stratification for…”
Get full text

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer by Cobo Dols, M., Villar Chamorro, E., Alés Díaz, I., Gil Calle, S., Alcalde García, J., Gutiérrez Calderón, V., Carabantes, F., Montesa Pino, Á., Bretón García, J. J., Benavides Orgaz, M.

“…Abstract only 17129 Background: This trial was designed to evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting…”
Get full text

Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer by Colomer, R., Mayordomo, J. I., Calvo, L., Hornedo, J., Carabantes, F., Gil, M., Martin, B., Cortes-Funes, H.

“…Abstract only…”
Get full text